Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2a, Dose-Escalation, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Intratumoral Administration of DTA-H19 in Patients With Unresectable Pancreatic Cancer

NCT00711997 is registered in ClinicalTrials.gov with Anchiano Therapeutics Israel Ltd. as lead sponsor.

NCT NCT00711997
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00711997 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2a, Dose-Escalation, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Intratumoral Administration of DTA-H19 in Patients With Unresectable Pancreatic Cancer
Lead sponsor
Anchiano Therapeutics Israel Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
August 31, 2009
Completion date
December 31, 2010
Enrollment
9 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic neoplasms